We invite all our readers to take part in our Hybridan Newsletters
and Equity Research Survey by clicking on the link: here
* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
Last Friday, IDOX (IDOX.L) left AIM
What’s baking in the oven?
Potential IPOs:***
21 May: Coastal Africa Group, a newly formed incorporated Company focused on acquiring and investing in the oil and gas sector, energy infrastructure, energy services and energy assets across West Africa, has announced its intention to IPO onto AIM. The expected Admission date is anticipated early June 2026.
17 March: Vista Parcs Group has announced its intention to IPO onto AIM. The newly incorporated entity is proposing to acquire a portfolio of 13 UK-based holiday and residential parks currently owned by Barney Group 2 Ltd (BG2) and operated by Baslow Parks Ltd. Deal details TBC and expected Admission date anticipated late June 2026.
Reverse Transactions:***
19th December 2025: Talon Resources (TAR.L), previously Medcaw Investments, the Company focused on identifying and acquiring prospective mining projects in the precious metals sector, with a primary focus on gold and other high-value commodities announced that it has entered into binding heads of terms (which includes an exclusivity agreement until 31 October 2026) with Ulvestone Ltd in respect of the proposed acquisition by the Company of 90% of the legal and beneficial interest in certain mineral exploration licences located in Ontario, Canada. The aggregate consideration payable by Medcaw is £4.17m, to be satisfied £70k in cash on execution of the definitive share purchase agreement, £100k in cash on AIM Admission, and £4m satisfied through the issue of new ordinary shares in Medcaw at a price of 1.5p per share, to be issued on AIM Admission. The indicative timetable in relation to the Cancellation and proposed re-admission to trading on AIM has been revised and is now expected to take effect on 23 June.
Banquet Buffet****
London Stock Exchange: Main Market and AIM
Crism Therapeutics 11.50p £5.83m (CRTX.L)
The UK clinical-stage drug delivery Company focused on the localised and sustained delivery of chemotherapy drugs has been awarded a grant. The non-dilutive research and development grant is for up to £99,902 and is from Invest Northern Ireland. The grant represents 61% of eligible project expenditure, to support the continued development of its docetaxel-ChemoSeed programme for the treatment of prostate cancer. The funded programme of work is scheduled to run through to March 2027 and reflects the commercial potential of the platform’s application in prostate cancer, one of the largest oncology markets globally. The funds will help to unlock the value of the ChemoSeed platform technology, which could also be applicable across multiple therapeutic indications.
Eco Buildings Group 12.00p £14.57m (ECOB.L)
The construction Company focused on advanced sustainable housing solutions announced the launch of Eco Buildings United Kingdom Ltd (EBUK), a dedicated United Kingdom subsidiary established to address growing demand for scalable, energy efficient and economically viable housing solutions across the UK.
The Company believes the establishment of EBUK represents a strategically significant step in the Group's expansion strategy and positions Eco Buildings directly within one of the most supply constrained housing markets in Europe. To support this expansion, Eco Buildings has entered into a binding framework agreement with Messrs Ben Thompson and Alister Bennett through their SPV (Noventum), creating a local operating platform combining Eco Buildings' proprietary construction technology with highly experienced UK and international construction and project management expertise.
EnSilica 120.5p £133.6m (ENSI.L)
The fabless microchip maker announced a new 7-year manufacturing and supply contract to produce an Arm based sensing chip for a German manufacturer of automotive components. As the chip is already in production, no design or tape-out is required. EnSilica will now be responsible for the manufacturing and supply of the chip to the customer. The Contract is expected to generate around $75m in revenue over seven years, with approximately $4 of revenue expected in the financial year ending 31 May 2027, with a gross margin reflecting the manufacturing-only nature of the Contract.
Gana Media Group 0.23p £39.02m (GANA.L)
The sports entertainment and digital gaming Company announced the launch of its newly developed, proprietary tournament pool betting product, The Quiniela Mundial 2026 ahead of the 2026 FIFA World Cup. The product has been fully developed internally by Gana and will be deployed directly via the Company's licensed Mexican online casino and sportsbook brand, Estadio Gana. To drive rapid user acquisition and mass market volume ahead of the tournament, Gana has committed a guaranteed minimum total prize fund of $100,000 Mexican Peso to the pool, complemented by weekly performance-based prizes and exclusive player bonuses. By owning the product end-to-end, Gana retains 100% of the player database growth, promotional flexibility, and downstream cross-selling margins, maximising the commercial lifetime value of acquired users during this major global sporting event.
Itaconix 112.0p £14.16m (ITX.L)
The innovator in high-performance plant-based specialty polymers used in consumer products announced progress in its ongoing assessment of crop production applications for its polymer technologies.
Itaconix is evaluating a promising polymer this growing season with field trials in the US under the tradename BioVail GRZ 200L. The Company is working directly with a small number of farms to assess the growth benefits from the application of BioVail GRZ 200L on corn crops. Full quantification of plant growth results is expected after harvest. If the results show potential benefits, then the Company will progressively increase the size and scope of trials over the next few years to confirm and substantiate claims to support full commercial efforts.
Litigation Capital Management 3.30p £4.75m (LIT.L)
The alternative asset manager specialising in dispute financing solutions internationally announced that the debt covenant waiver from Northleaf that was due to expire on 30 May has been extended to 30 June 2026. During the extended waiver period, the interest on the loan remains increased by 2.00% per annum consistent with the initial waiver. LCM has recently received negative developments in relation to two of its case investments. These two matters have a combined LCM invested capital of approximately A$9m. Management is reviewing these matters and expects to recognise material write-downs in relation to these investments in its next set of financial statements. The Strategic Review that was first announced on 15 September 2025 continues to progress and the waiver extension is reflective of Northleaf's ongoing support, while LCM works towards a long-term resolution of its capital position. Management will provide an update on the progress of the Strategic Review in due course.
LPA Group 68.5p £9.26m (LPA.L)
The innovation led engineering Company that designs and manufactures electronic and electro-mechanical components and systems reports its interims today to 31 March 2026. Revenue has increased 45% to £13.8m and the results show an EBITDA positive of £1m from a loss of £0.5m in the year to 31 March 2025 and leading to a PBT of £0.4m against a loss of £0.5m in the year to 31 March 2025. The debt, as a percentage of equity, increased to 34.8% from 24.1% in the year to 31 March 2025. The Group is growing revenue in line with the stated 5-year plan with a target of achieving organic revenue growth 50% higher in 2028 than in 2024. Rail is the heart of the business and will continue to play a critical role in maintaining a consistent flow of work, however the diversification strategy is focusing on market adjacencies and innovation is making progress in the uncertain global political landscape. Aerospace and Defence has had a solid start to the year. Generally, the outlook is encouraging, and the CEO is confident of delivering full-year results in line with current market expectations.
Nativo Resources 0.35p £3.5m (NTVO.L)
The growth-focused natural resources Company with gold mining and processing interests in Peru announced its audited final results for the year ended 31 December 2025. During the period, Nativo transitioned into a focused Peruvian gold mining and processing business with a clear near-term production strategy and progressed development plans for La Patona Gold Ore Processing Plant (GOPP), targeted for commissioning in H2 2026. The Company also secured an option over the Toma La Mano tailings project in Peru, supporting the Company's strategy to develop scalable tailings recovery operations.
Nativo completed a significant restructuring of the Company's balance sheet and funding profile during 2025 and raised approximately £3m during the year through a combination of equity and structured funding instruments. Nativo ended the year the year with cash balances of US$1.81m (31 December 2024: US$0.05mi).
TPXimpact Holdings 55.50p £50.45m (TPX.L)
The digital transformation partner announced that it has been selected as the successful bidder for a £16m, 2-year contract with the Ministry of Justice (MoJ). Following a competitive tender process, the Company has been awarded Product Team Bench Model Services. This award builds upon TPXimpact's existing work within the Ministry of Justice, supporting His Majesty's Prison and Probation Service to deliver digital transformation across Probation Services. This £16m award brings total new business for the first two months of FY27 to £31m. This follows a series of new win announcements and contract uplifts in the last quarter of FY26 - DEFRA (£39m), NHS England (£22m) and HMLR (£11m).
Aquis Market:
ProBiotix Health 7.25p £11.47m (AQSE: PBX)
The life sciences business developing probiotics to support cardiometabolic health announced a new partnership agreement with Slovakia based iProbio. ProBiotix secured a commercial cooperation with iProbio to supply its patented probiotic strain LP LDL for a new cardiometabolic health food supplement branded as CARDIObiom+, a product developed by the iProbio consumer brand of PerBiotiX s.r.o., a leading Slovak based probiotics company. Cardiovascular disease mortality in Slovakia is estimated to be around 50% higher than the EU average, while hypercholesterolaemia is estimated to affect approximately 49% of adults in the country, reinforcing the importance of supporting cardiovascular and metabolic health. CARDIObiom+ was officially launched in Slovakia to coincide with World Hypertension Day, and a global awareness campaign focused on cardiovascular health.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
